5 Value and Growth Medtech Stories
Streetwise is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
The not-so-secret ingredient necessary for growth in medtech is innovation. Unless new prosthetics and instruments are differentiated from their predecessors, clinicians just won’t look at them because they are inherently resistant to change without an incentive. “The advantage of a new technology, a new product, a little better mousetrap or a lot better mousetrap, is you will drive higher pricing,” says Analyst and Managing Director William Plovanic of Canaccord Genuity. “Of course, if you're just starting up, it will drive a significantly higher price. If you have an existing company that you're building, it will help offset price degradation in your core, commoditized product lines.”
When I spoke with Plovanic for his interview with The Life Sciences Report, I was hoping to hear about small-cap growth stories where binary events can give investors either quick doubles or ugly haircuts, but Plovanic steered the conversation to the low-end mid-cap space with three initial names in the $1–$1.7 billion market cap range. I asked him to go ahead with his best idea. “Our top growth picks for 2013 are DexCom (NASDAQ: DXCM) and Insulet (NASDAQ: PODD),” he said. So off the bat he goes with two diabetes companies. “Both of these companies have new product approvals from the FDA.” For DexCom, it was the PMA (Premarket Approval) clearance of its DexCom G4 Platinum continuous glucose monitoring device with improved accuracy in the hypoglycemic range. For Insulet, it was the FDA clearance for its 510(k) (Premarket Notification, or PMN) device, the OmniPod System, which is the first-ever tubeless insulin pump. “It’s smaller and lighter than the original with the same 200-unit insulin capacity,” he says. “The advantage to both DexCom and Insulet is significantly improved gross and operating margins.” Moreover, “Both of these companies are fast-growing medical device companies as is,” he says, “And now with newer products they will at least maintain, if not accelerate, those top line growth rates.”
Knowing that I want to talk about companies that grow like weeds, Plovanic just gets the issue out on the table. “There are not a lot of fast-growth companies out there,” he says. But, “It depends how you define growth. One of our top value picks could almost be defined as a growth play.” He’s referring to Globus Medical Inc. (NYSE: GMED), which has a $1.7 billion market cap, is an innovative player in spine, and is growing its top line in the range of 10%–15% per year. And, “Its bottom line should grow at least 10%–15% per year,” he says. “It has numerous new product cycles, but nothing specific that we can point to. It's just more about the stock having a very inexpensive valuation.” Globus has a distinctive pipeline development program that has produced more than 100 new products over the last decade when the company was founded. The company is growing its distribution channels, and Plovanic sees margins as being sustainable for the foreseeable future.
He also likes NuVasive (NASDAQ: NUVA), which, like Globus, preannounced strong Q4 2012 results. Plovanic likes the small to mid-level spine-oriented companies that he believes are best positioned to carve out market share in spite of a less-than-stellar overall outlook in spine. The company is expanding its sales force, and there is potential for bringing in displaced salespeople from the merger of Johnson & Johnson with Synthes. The company is also building outside the U.S., with Japan set to provide a new revenue source with the launch of is extreme lateral interbody fusion (XLIF) system, which enables access to the intervertebral lumbar disc space laterally, and not from the patient’s front or back. The bottom line for Plovanic is that NuVasive carries on as the “gold standard” in the lateral access and minimally invasive surgery market segments. But there are also new growth areas with its AttraX biologics and PCM cervical disc products, the latter of which just received FDA approval in Q4 2012. “You're looking at a core growth rate in the mid-single digit range,” he says. “There is a lot of earnings leverage potential with NuVasive. It’s a value play because it's a show-me story. It needs to show that it can string together two, three, four quarters, and the stock will perform pretty significantly if it does that.”
To read the entire interview with William Plovanic, visit www.thelifesciencesreport.com.
StreetWiseReport has no position in any stocks mentioned. From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise. Streetwise Reports does not accept stock in exchange for services or render general or specific investment advice and do not endorse or recommend the business, products, services or securities of any industry or company mentioned in this report. Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!